Table 4.

Tacrolimus dose and levels and corticosteroid dose by MPA dose changes at 1, 3, 6, and 12 months post-transplant

		Tacrolimusb
	MPA dose since last visita	Dose (mg/d)	Trough concentration (ng/mL)	Corticosteroids Dose (mg/d)
Month 1	No dose change	7.0 (4.7) n = 751	9.7 (4.7) n = 746	15.6 (24.3) n = 475
	Dose change	7.1 (4.6) n = 77	8.6 (3.2) n = 77	15.2 (6.7) n = 29
	p Valuec	0.861	0.047	0.928
Month 3	No dose change	6.2 (4.1) n = 634	9.3 (3.9) n = 624	10.1 (25.2) n = 393
	Dose change	6.7 (4.2) n = 129	9.0 (3.7) n = 127	8.7 (8.5) n = 56
	p Valuec	0.225	0.310	0.684
Month 6	No dose change	6.0 (3.6) n = 511	8.1 (3.2) n = 498	6.6 (4.6) n = 325
	Dose change	5.6 (3.5) n = 138	7.7 (3.2) n = 133	6.6 (3.7) n = 87
	p Valuec	0.174	0.213	0.956
Month 12	No dose change	5.6 (3.6) n = 413	7.7 (3.2) n = 402	6.5 (6.9) n = 263
	Dose change	5.3 (2.9) n = 63	6.7 (2.1) n = 61	6.2 (7.7) n = 52
	p Valuec	0.570	0.014	0.751

MPA, mycophenolic acid.

Doses are shown as mean (SD). MPA dose change included dose reduction, interruption, or discontinuation.

^aFor patients in whom tacrolimus exposure was known at each time point.

^bOutliers excluded at months 1, 6 and 12.

^cFor MPA dose vs. no MPA dose change.